{Reference Type}: Case Reports
{Title}: Mycophenolate Mofetil in the Treatment of Severe Corticosteroid-Dependent or Corticosteroid-Resistant Nail Lichen Planus: A Case Series of 5 Patients.
{Author}: Duplaine A;Cogrel O;
{Journal}: Skin Appendage Disord
{Volume}: 8
{Issue}: 5
{Year}: Sep 2022
暂无{DOI}: 10.1159/000524246
{Abstract}: <B>UNASSIGNED: </B>Recent expert recommendations suggest mycophenolate mofetil (MMF) as a third-line therapy, in severe corticosteroid-dependent or corticosteroid-resistant nail lichen planus (NLP). However, there is currently no literature to support MMF use in this indication. This is a retrospective monocentric French case series of 5 patients with severe corticodependant or corticoresistant NLP treated by oral MMF (2-3 g/day), between 2013 and 2021.<BR><B>UNASSIGNED: </B>The primary outcome was therapeutic success in a target fingernail. All 5 patients showed some clinical improvement, ranging from mild improvement (1/5) to clinical cure (2/5). Clinical improvement was more significant when the drug was taken for a longer period (24 months vs. 4 months) and at a higher dose (3 g/day vs. 2 g/day). Relapse occurred after stopping or tapering the MMF dose. MMF was well tolerated.<BR><B>UNASSIGNED: </B>MMF may be a treatment to consider for severe corticosteroid-dependent or corticosteroid-resistant NLP. The long-term safety of this treatment warrants further investigation.